Prostate cancer (PCa) is the most widely diagnosed male cancer in the Western World and
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …

Simple Summary Prostate cancer can develop under hormone treatment and chemotherapy
from a castration-sensitive towards a castration-resistant into a drug resistant-tumor. The …

Despite the initial efficacy of androgen deprivation in prostate cancer, virtually all patients
progress to castration-resistant prostate cancer (CRPC). Androgen receptor (AR) signaling …

The role of the androgen receptor (AR) signaling axis in the progression of prostate cancer
is a cornerstone to our understanding of the molecular mechanisms causing castration …

Androgen receptor (AR), a ligand-dependent nuclear transcription factor and a member of
steroid hormone receptor family, plays an important role in prostate organogenesis by …

Context Various molecular mechanisms play a role in the development of resistance to
androgen deprivation therapy in castration-resistant prostate cancer (CRPC). Objective To …

Around 80–90% of prostate cancer (PCa) cases are dependent on androgens at initial
diagnosis; hence, androgen ablation therapy directed toward a reduction in serum …

BACKGROUND Significant progress in understanding the molecular basis of castration
resistant prostate cancer (CRPCa) has been achieved in recent years. Despite this progress …

Androgen receptor (AR) signaling is a critical pathway for prostate cancer cells, and
androgen-deprivation therapy (ADT) remains the principal treatment for patients with locally …

Activation of the androgen receptor (AR) and AR-driven transcriptional programs is central to
the pathophysiology of prostate cancer. Despite successful translational efforts in targeting …